What's Happening?
The Department of Justice (DOJ) has revised two sections of its enforcement manual concerning the False Claims Act (FCA), signaling a ramp-up in fraud enforcement efforts. These revisions impact how the DOJ evaluates cases, makes intervention decisions,
and utilizes evidence in FCA cases. One key change is that agency guidance documents, such as CMS Medicare manuals, cannot independently establish FCA liability. While noncompliance with guidance alone is insufficient for an enforcement action, the DOJ can still use these documents as evidence to demonstrate a defendant's knowledge of legal requirements, as proof of industry standards, or to support or challenge expert opinions. The second significant revision addresses the DOJ's authority to dismiss qui tam actions, which are lawsuits filed by private citizens on the government's behalf. The revised Justice Manual now mandates that DOJ attorneys assess in every declined case whether dismissal is warranted, and it broadens the scope for dismissing 'meritless qui tams.' This policy builds on the Supreme Court's 2023 decision in *United States ex rel. Polansky v. Executive Health Resources, Inc.*, which affirmed the DOJ's ability to seek dismissal even after initially declining to intervene.
Why It's Important?
These revisions to the Justice Manual are important for companies and individuals operating in sectors heavily scrutinized for fraud, such as healthcare and importing. The change regarding agency guidance documents offers some clarity and potential relief for defendants, as noncompliance with guidance alone will not be sufficient to establish FCA liability. However, the broad range of permissible uses for guidance documents means they will likely remain a significant factor in FCA litigation. The increased emphasis on dismissing 'meritless qui tams' could benefit defendants by reducing the burden of defending against weak lawsuits, particularly in cases where the government declines to intervene. Conversely, the DOJ's broader fraud enforcement initiatives, including the establishment of the National Fraud Enforcement Division and its identified priorities, indicate a more aggressive stance against fraud. This means that while some procedural aspects might favor defendants, the overall environment for fraud enforcement is intensifying, requiring companies to maintain robust compliance programs.
What's Next?
Companies that interact with federal funds, including healthcare providers, government contractors, and importers, should anticipate increased scrutiny and enforcement actions. The DOJ's National Fraud Enforcement Division has outlined five key priorities: public trust and financial integrity, healthcare, internal revenue, global trade and commerce, and corporate misconduct. Healthcare companies should review their billing, telemedicine, and marketing practices, while importers need to ensure the accuracy of country-of-origin, classification, and valuation declarations to avoid customs-related FCA exposure. The expansion of the Health Care Fraud Strike Force model, coupled with enhanced data analytics, suggests a more sophisticated approach to identifying and prosecuting healthcare fraud. Defendants facing qui tam cases should consider requesting the DOJ to exercise its dismissal authority, especially in cases perceived as weak or burdensome. The revisions underscore a dynamic enforcement landscape where compliance and proactive risk management will be crucial for businesses.
Beyond the Headlines
The DOJ's revised FCA playbook reflects a strategic recalibration of its enforcement mechanisms, balancing the need to combat fraud effectively with concerns about potentially overreaching interpretations of liability. The emphasis on distinguishing between binding regulations and non-binding guidance documents could lead to more precise legal arguments in FCA cases, potentially reducing the scope for ambiguous claims. However, the DOJ's simultaneous expansion of fraud enforcement resources and the creation of specialized divisions, such as the National Fraud Enforcement Division and the Fraud and Asset Recovery Division, indicate a long-term commitment to aggressively pursuing fraudulent activities. This dual approach suggests that while the legal framework for FCA cases might become more refined, the sheer volume and intensity of investigations are likely to increase. This could lead to a greater number of settlements and prosecutions, impacting various industries and potentially shaping corporate compliance practices for years to come. The focus on areas like global trade and healthcare also highlights the economic and societal significance of these enforcement efforts.
